21 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Partial Correlation Between Pelvis Displacement and Paretic Step Width During Gait (Change From Baseline)Primary· baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks
A custom measure that quantifies the strength of the relationship between body mechanics and foot placement. This measure falls within a relatively narrow range among neurologically intact controls, but is substantially reduced in some individuals who have experienced a stroke, indicating a reduced ability to stabilize their gait pattern. This measure relates the mechanical state of the body at the start of each step (mediolateral pelvis displacement and velocity of the pelvis relative to the stance foot) to the step width at the end of the step. Specifically, the partial linear correlation be
A commonly-used clinical test to quantify balance and stability during various walking tasks. The minimum value is 0, the maximum value is 30, and higher scores indicate better outcomes. The total maximum value of 30 is calculated as the sum of 10 subscores, each of which has a scoring range of 0-3 and represents a distinct walking task.
The change in this measure relative to baseline is calculated at four time points (after 4, 8, 12, and 24 weeks).
A commonly-used clinical scale that quantifies an individual's confidence in performing various tasks requiring balance. The minimum value is 0, the maximum value is 100, and higher scores indicate a better outcome. The overall score is calculated as the mean of 16 subscores, each of which can range of 0 to 100 and represents self-efficacy at a distinct movement task.
The change in this measure relative to baseline is calculated at four time points (after 4, 8, 12, and 24 weeks).
4-week assessment
Group
Value
95% CI
Error Reduction
2.2
± 11.2
Error Augmentation
-0.6
± 6.9
Activity Matched Control
3.7
± 10.3
8-week assessment
Group
Value
95% CI
Error Reduction
2.5
± 12.9
Error Augmentation
-1.2
± 4.9
Activity Matched Control
4.1
± 16.2
12-week assessment
Group
Value
95% CI
Error Reduction
6.1
± 16.4
Error Augmentation
2.8
± 6.8
Activity Matched Control
5.4
± 12.5
Follow-up assessment (after 12 weeks)
Group
Value
95% CI
Error Reduction
8.1
± 14.7
Error Augmentation
4.6
± 7.9
Activity Matched Control
3.7
± 22.8
10-meter Walk Test (Change From Baseline)Secondary· baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks
A commonly-used clinical test to quantify general gait function. Walking speed is measured during the middle 6-meter portion of a 10-meter straight line path.
The change in this measure relative to baseline is calculated at four time points (after 4, 8, 12, and 24 weeks).
4-week assessment
Group
Value
95% CI
Error Reduction
0.01
± 0.08
Error Augmentation
0.03
± 0.08
Activity Matched Control
0.03
± 0.08
8-week assessment
Group
Value
95% CI
Error Reduction
0.02
± 0.10
Error Augmentation
0.04
± 0.07
Activity Matched Control
0.04
± 0.10
12-week assessment
Group
Value
95% CI
Error Reduction
0.05
± 0.14
Error Augmentation
0.02
± 0.08
Activity Matched Control
0.06
± 0.10
Follow-up assessment (after 12 weeks
Group
Value
95% CI
Error Reduction
0.01
± 0.15
Error Augmentation
0.01
± 0.11
Activity Matched Control
0.01
± 0.11
Fall IncidenceSecondary· 6 months (during 12 week follow-up period)
Self-report history of fall occurrence, quantified by the average number of falls per participant in each group during the 12-week period that followed completion of the study's intervention component
Group
Value
95% CI
Error Reduction
0.50
± 0.20
Error Augmentation
0.29
± 0.14
Activity Matched Control
0.62
± 0.23
Fear of FallingSecondary· 6 months (at completion of 12-week Follow-up period)
Self-report statement of whether a participant has a fear of falling
Group
Value
95% CI
Error Reduction
4
Error Augmentation
5
Activity Matched Control
4
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data were collected over a three-year period, corresponding from the time when the first participant was enrolled into the intervention to the time when the overall intervention ended..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to determine whether a novel treadmill training intervention can improve the gait stabilization strategy used by individuals who have experienced a stroke.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke
· recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment
· NA
· recruiting
NCT07356011 — Exoskeleton for Balance
· NA
· recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in
· NA
· recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients
· NA
· recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care
· Phase 1
· not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran
· NA
· not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness
· NA
· not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
· NA
· not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 3 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02964039.